121077-11-0|KU-2285|2,2-difluoro-N-(2-hydroxyethyl)-3-(2-nitro-1H-imidazol-1-yl)propanamide|-范德生物科技公司

KU-2285

NMR下载 COA and HPLC MSDS下载
names：
2,2-difluoro-N-(2-hydroxyethyl)-3-(2-nitro-1H-imidazol-1-yl)propanamide
CAS号：
121077-11-0
MDL Number：
MF(分子式)： C8H10F2N4O4 MW(分子量)： 264.19
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
FMK16971-100mg	100mg	>98%	¥ 0.00	¥ 0.00		Get quote	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	KU-2285
英文别名	KU2285; KU-2285; KU 2285.
CAS号	121077-11-0
Inchi	InChI=1S/C8H10F2N4O4/c9-8(10,6(16)11-2-4-15)5-13-3-1-12-7(13)14(17)18/h1,3,15H,2,4-5H2,(H,11,16)
InchiKey	VOXUFOPZGRTSJY-UHFFFAOYSA-N
分子式 Formula	C8H10F2N4O4
分子量 Molecular Weight	264.19
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	KU-2285(CAS:121077-11-0):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	KU-2285 is a potent hypoxic cell radiosensitizer. At less than 100 mg/kg, KU-2285 sensitized SCCVII tumors more than MISO and SR-2508 by fractionated irradiation. KU-2285 entered clinical trials in late 1990s.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Shibamoto Y, Ohshio G, Hosotani R, Nishimura Y, Manabe T, Imamura M, Abe M. A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy. Br J Cancer. 1997;76(11):1474-9. PubMed PMID: 9400944; PubMed Central PMCID: PMC2228186.

[2]Shibamoto Y, Takahashi M, Abe M. A phase I study of a hypoxic cell sensitizer KU-2285 in combination with conventional radiotherapy. Radiother Oncol. 1996 Jul;40(1):55-8. PubMed PMID: 8844888.

[3] Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Abe M. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation. Jpn J Cancer Res. 1996 Jan;87(1):98-104. PubMed PMID: 8609056.

[4] Oya N, Shibamoto Y, Shibata T, Murata R, Iwai H, Sugiyama T, Abe M. KIN-804 vs. KU-2285 as a radiosensitizer for clinical use. Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):595-600. PubMed PMID: 8005822.

[5] Iwai H, Matsuno E, Sasai K, Shibamoto Y, Abe M. Radiosensitizing activity and pharmacokinetics of multiple dose administered KU-2285 in peripheral nerve tissue in mice. Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):591-4. PubMed PMID: 8005821.

6: Shibata T, Shibamoto Y, Oya N, Sasai K, Murata R, Ishigaki T, Abe M. Comparison of radiosensitizing effect of KU-2285 and SR-2508 at low drug concentrations and doses. Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):587-90. PubMed PMID: 8005820.7: Shibamoto Y, Kitakabu Y, Murata R, Oya N, Shibata T, Sasai K, Takahashi M, Abe M. Reoxygenation in the SCCVII tumor after KU-2285 sensitization plus single or fractionated irradiation. Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):583-6. PubMed PMID: 8005819.8: Oya N, Shibamoto Y, Sasai K, Sugiyama T, Abe M. In vivo radiosensitization efficacy of KU-2285 and etanidazole at clinically relevant low radiation doses. Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1113-9. PubMed PMID: 8262836.9: Shibamoto Y, Streffer C, Sasai K, Oya N, Abe M. Radiosensitization efficacy of KU-2285, RP-170 and etanidazole at low radiation doses: assessment by in vitro cytokinesis-block micronucleus assay. Int J Radiat Biol. 1992 Apr;61(4):473-8. PubMed PMID: 1349329.10: Sasai K, Fushiki M, Yukawa Y, Suyama S, Iwai H, Shibamoto Y, Nishimoto S, Takahashi M, Abe M. In vivo radiosensitizing activity of a new fluorinated hypoxic cell radiosensitizer, KU-2285, in combination with radiation dose fractionation. Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1231-4. PubMed PMID: 1938521.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开